Followers of the twisted tale of DeepCapture may remember that on August 12, 2005, I gave a webcast of which I will always remain proud. It was titled, "The Miscreant's Ball".
As you encounter conversations on this topic in the days to come, it is a good opportunity to point out that Deep Capture published irrefutable evidence of insider trading at short selling hedge funds SAC Capital, Kynikos Associates and Third Point Partners almost one year ago.
14 July 2009 by Mark Mitchell
How the criminal Michael Milken and friends captured the Food and Drug Administration, derailed a promising treatment for prostate cancer, and made a boat load of cash in the process.
11 July 2009 by Mark Mitchell
More about Michael Milken's "philanthropy" and the unprecedented lobbying campaign that derailed Dendreon, a company with a promising treatment for prostate cancer. Also, we learn the identity of another miscreant hedge fund.
09 July 2009 by Mark Mitchell
Today we find that people tied to Michael Milken's Prostate Cancer Foundation and Michael Milken's ProQuest Investments distorted the public discourse in order to derail a promising treatment for prostate cancer.
05 July 2009 by Mark Mitchell
Today we deliver the skinny on UBS, the investment bank. Also, more on Michael Milken's investment fund, Michael Milken's "philanthropic" outfit, and some singularly strange occurrences.
03 July 2009 by Mark Mitchell
The Dendreon saga continues. Today we meet another shady financial analyst, and begin to understand how the criminal Michael Milken stood to profit from the demise of the company with the only promising new treatment for prostate cancer.
01 July 2009 by Mark Mitchell
In Chapter 6 of the Dendreon drama, we meet a shady financial analyst and learn more about a destructive network of short sellers and miscreants.
29 June 2009 by Mark Mitchell
In the latest chapter of this drama, CNBC's Jim Cramer makes "a mistake" -- again! -- while yet another of his hedge fund friends bets big against Dendreon, a company with a promising treatment for prostate cancer.
26 June 2009 by Mark Mitchell
In the latest chapter of this on-going series, we identify two more of the "colorful" hedge funds that hoped to profit from the demise of Dendreon, a company with a promising treatment for prostate cancer.
24 June 2009 by Mark Mitchell
It's time to learn the identities of the seven hedge funds that bet big against Dendreon. We'll start with a firm that's been in the news a bit lately...
21 June 2009 by Mark Mitchell
A brutal attack on Dendreon, a company with a promising treatment for prostate cancer, raises questions about the integrity of our financial markets. Meanwhile, we ponder the work of seven colorful hedge fund managers and a famous criminal named Michael Milken.
